Gilead Sciences, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹1.7L Cr
- HIV sales expected to grow 8% year-over-year in 2026, up from prior 6% growth guidance. - Gilead expects full-year 2026 operating income of $2.4 billion to $2.9 billion, factoring in acquisitions and related expenses.
From Gilead Sciences, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹136.22
Market Cap
₹1.7L Cr
P/E Ratio
18.2
Revenue Rank
Margin Rank
How does Gilead Sciences, Inc. rank in Biotechnology?
Compare Gilead Sciences, Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →HIV sales expected to grow 8% year-over-year in 2026, up from prior 6% growth guidance.
- →Yeztugo sales forecasted at approximately $1 billion in 2026, increased from $800 million earlier.
- →Total 2026 product sales anticipated between $30 billion and $30.4 billion, a $400 million increase.
- →Base business growth projected at 5%-6% for 2026, reflecting strong commercial momentum.
- →Antito-cel launch revenue expected to begin in early 2027, targeting a $3.5 billion fourth-line-plus CAR-T market.
- →Up to 4 additional product launches planned before end of 2026.
- →Five Phase III trial updates anticipated in 2026, supporting pipeline growth.
- →Steady market expansion in HIV prevention with Yeztugo's increased uptake in both naive and switch patient segments.
- →Continued commercial outperformance and disciplined expense management expected to sustain margin strength.
📈 Profitability & Margins
Rank 3- →Gilead expects full-year 2026 operating income of $2.4 billion to $2.9 billion, factoring in acquisitions and related expenses.
- →Excluding upfront payments from acquisitions, operating income is projected between $14 billion and $14.5 billion, an increase of $200 million from prior guidance.
- →Full-year 2026 non-GAAP loss per share is guided between $1.05 and $0.65 due to acquisition costs; excluding these, non-GAAP diluted EPS is $8.45 to $8.85, consistent with earlier guidance.
- →The company anticipates manageable incremental expenses in 2026 and 2027 due to acquisitions with room for margin expansion beyond 2027, supported by portfolio growth.
- →Expect continued strong financial performance with potential to strengthen margins over time, despite quarter-to-quarter variability.
- →Near-term business development focuses on integration and clinical momentum, with limited large M&A expected in 2026.
🏗️ Capital Expenditure Plans
Yes- →Gilead has made multiple recent strategic acquisitions: Arcellx (closed), Ouro Medicines and Tubulis (expected to close soon), adding best-in-class CAR-Ts, T cell engagers, antibody-drug conjugates, and novel technologies.
- →They plan to invest in clinical programs related to these acquisitions, driving a mid-single-digit percentage increase in R&D expenses for 2026.
- →Upfront IPR&D investments of approximately $11.8 billion are planned for 2026, including upfront payments associated with these acquisitions.
- →The company will focus on closing and integrating these acquisitions, maintaining strong clinical momentum.
- →While large M&A deals are less likely in 2026, Gilead remains open to strategic acquisitions if compelling opportunities arise.
- →Continued investments in product launches and pipeline development, including cell therapy (anito-cel), once-yearly HIV prevention (Yeztugo), and ADC platform expansion through Tubulis technology.
- →Emphasis on disciplined financial management to absorb acquisition-related expenses while maintaining margin expansion.
💰 Fundraising & Capital Structure
No information- →The company expects incremental financing expenses in 2026 related to recent acquisitions (Arcellx, Ouro Medicines, Tubulis), contributing to about $400 million in incremental expenses, with a portion being financing expenses.
- →Despite these expenses, the company is effectively offsetting the impact with revenue outperformance and disciplined expense management.
- →They mention transaction financing expenses amounting to approximately $9.50 per share reflected in the EPS guidance for 2026.
- →There is no explicit mention of plans for new fundraising through additional debt or equity in the immediate future.
- →The management indicated it is less likely that they will pursue sizable M&A this year but remain open to strategic acquisitions if compelling opportunities arise.
- →Current financial strategy emphasizes disciplined financial management and operational expense prioritization without signaling imminent fundraising events.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Gilead Sciences, Inc. Q2 FY26 results?
- HIV sales expected to grow 8% year-over-year in 2026, up from prior 6% growth guidance. - Gilead expects full-year 2026 operating income of $2.4 billion to $2.9 billion, factoring in acquisitions and related expenses.
What is Gilead Sciences, Inc. share price analysis?
Gilead Sciences, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 18.2 with a market cap of $169,127. Investors should review the full earnings analysis for detailed insights.
Is Gilead Sciences, Inc. planning capital expenditure?
- Gilead has made multiple recent strategic acquisitions: Arcellx (closed), Ouro Medicines and Tubulis (expected to close soon), adding best-in-class CAR-Ts, T cell engagers, antibody-drug conjugates, and novel technologies.
Keep Gilead Sciences, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.